Latest Daiichi Sankyo Stories
- Committee votes 9 to 1 to recommend approval of once-daily SAVAYSA for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF) TOKYO,
SAN DIEGO, Oct.
BOSTON, Oct. 22, 2014 /PRNewswire-USNewswire/ -- The Center for Connected Health today announced a co-development agreement with Daiichi Sankyo, Inc.
RnRMarketResearch.com adds “Osteoporosis & Osteoarthritis – Pipeline Review, H2 2014” to its store.
TOKYO and SAN DIEGO, Oct. 14, 2014 /PRNewswire/ -- On Friday October 10, U.S.
NEW YORK, Oct.
PRINCETON, N.J., Oct. 1, 2014 /PRNewswire/ -- Ranbaxy Laboratories Inc.
Lead Compound, Quizartinib, Will Further Build Daiichi Sankyo Oncology Pipeline TOKYO and SAN DIEGO, Sept. 28, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Ltd.
- A trick or prank.